• Latest Posts

Five companies racing to bring their NASH treatments toward the finish line

Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered

Weekly Roundup 24 Nov 2023

Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA 

Beyond insulin: six cutting-edge diabetes biotech companies you should know about

Weekly Roundup 10 Nov 2023

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

In Depth 8 Nov 2023

Promising cure for COPD: is a breakthrough treatment within reach?

In Depth 2 Nov 2023

How French pharma giant Sanofi is betting big on AI